{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:14:53Z","timestamp":1791648893346,"version":"4.3.4"},"reference-count":75,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Chronic pain imposes a substantial burden on global health and remains challenging to manage, despite ongoing advances in pharmacologic and interventional therapies. Recognition of chronic pain as a condition driven by central sensitization and neuroimmune dysregulation has prompted interest in therapies that target these mechanisms rather than peripheral nociception alone. Low-dose naltrexone (LDN), administered at doses substantially lower than those used for opioid or alcohol use disorders, has emerged as a repurposed treatment with potential analgesic and anti-inflammatory properties. This review summarizes the pharmacologic characteristics of LDN, with emphasis on its proposed mechanisms involving transient opioid receptor blockade, modulation of microglial activation, Toll-like receptor signaling, and central neuroimmune pathways. Available clinical evidence evaluating LDN across a range of chronic pain conditions, such as fibromyalgia, neuropathic pain syndromes, inflammatory and autoimmune disorders, headache disorders, and other centralized pain states, is critically reviewed. Although early trials, observational studies, and case series suggest potential benefit in selected populations, the overall evidence base remains limited, heterogeneous, and characterized by variability in dosing strategies and outcome measures. Safety, tolerability, and practical considerations relevant to contemporary pain practice are discussed, including interactions with opioid therapy and challenges related to off-label use. Finally, key gaps in the current evidence and priorities for future research are highlighted, underscoring the need for larger, well-designed randomized trials and mechanism-informed studies to better define LDN\u2019s role in multimodal chronic pain management.<\/jats:p>","DOI":"10.3390\/jpm16030151","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:22:14Z","timestamp":1772788934000},"page":"151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-Dose Naltrexone in Chronic Pain Management: Mechanisms, Evidence, and Clinical Implications"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3461-9335","authenticated-orcid":false,"given":"Alyssa","family":"McKenzie","sequence":"first","affiliation":[{"name":"School of Medicine, St. George\u2019s University, West Indies 11739, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6422-5852","authenticated-orcid":false,"given":"Tiffany","family":"Bittar","sequence":"additional","affiliation":[{"name":"School of Medicine, St. George\u2019s University, West Indies 11739, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4785-0733","authenticated-orcid":false,"given":"Rachel","family":"Dombrower","sequence":"additional","affiliation":[{"name":"School of Medicine, St. George\u2019s University, West Indies 11739, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dupinder","family":"Raman","sequence":"additional","affiliation":[{"name":"School of Medicine, St. George\u2019s University, West Indies 11739, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Hussain","sequence":"additional","affiliation":[{"name":"School of Medicine, St. George\u2019s University, West Indies 11739, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5436-0748","authenticated-orcid":false,"given":"Nitchanan","family":"Theeraphapphong","sequence":"additional","affiliation":[{"name":"School of Medicine, St. George\u2019s University, West Indies 11739, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1908-2638","authenticated-orcid":false,"given":"Sophia M.","family":"McKenzie","sequence":"additional","affiliation":[{"name":"School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.15585\/mmwr.mm7215a1","article-title":"Chronic pain among adults\u2014United States, 2019\u20132021","volume":"72","author":"Rikard","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: An update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMra1807061","article-title":"Nonnarcotic methods of pain management","volume":"380","author":"Finnerup","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40263-023-01018-3","article-title":"The utilization of low dose naltrexone for chronic pain","volume":"37","author":"Poliwoda","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11916-020-00898-0","article-title":"Low-dose naltrexone for chronic pain: Update and systematic review","volume":"24","author":"Kim","year":"2020","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/S0140-6736(21)00392-5","article-title":"Nociplastic pain: Towards an understanding of prevalent pain conditions","volume":"397","author":"Fitzcharles","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: Implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/pm\/pnad074","article-title":"Low-dose naltrexone\u2019s utility for non-cancer centralized pain conditions: A scoping review","volume":"24","author":"Rupp","year":"2023","journal-title":"Pain Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_15","first-page":"200","article-title":"Low-dose naltrexone for treatment of dermatologic conditions: A clinical review","volume":"94","author":"Zhou","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Toljan, K., and Vrooman, B. (2018). Low-dose naltrexone (LDN): Review of therapeutic utilization. Med. Sci., 6.","DOI":"10.3390\/medsci6040082"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/pm\/pnaa001","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: Investigation of dose\u2013response relationships","volume":"21","author":"Vaegter","year":"2020","journal-title":"Pain Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey\u2013Hailey disease)","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: A randomised, double-blind, placebo-controlled trial","volume":"6","author":"Christensen","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamadermatol.2024.4098","article-title":"Low-dose naltrexone use in biopsy-proven lichen planus of the nails","volume":"160","author":"Bray","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/pds.4201","article-title":"Low-dose naltrexone and opioid consumption: A drug utilization cohort study based on data from the Norwegian prescription database","volume":"26","author":"Raknes","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jackson, D., Singh, S., Zhang-James, Y., Faraone, S., and Johnson, B. (2021). The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.593842"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"148154","DOI":"10.1016\/j.brainres.2022.148154","article-title":"Antinociceptive effect of ultra-low-dose naltrexone in a preclinical model of postoperative orofacial pain","volume":"1798","author":"Hummig","year":"2023","journal-title":"Brain Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4)","volume":"28","author":"Hutchinson","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"McKenzie, A., Dombrower, R., Theeraphapphong, N., McKenzie, S., and Hijazin, M.A. (2026). Glial activation, neuroinflammation, and loss of neuroprotection in chronic pain: Cellular mechanisms and emerging therapeutic strategies. Biomedicines, 14.","DOI":"10.3390\/biomedicines14010058"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yang, G., Xu, X., Gao, W., Wang, X., Zhao, Y., and Xu, Y. (2025). Microglia-orchestrated neuroinflammation and synaptic remodeling: Roles of pro-inflammatory cytokines and receptors in neurodegeneration. Front. Cell. Neurosci., 19.","DOI":"10.3389\/fncel.2025.1700692"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/15230864251401591","article-title":"Cytokine\u2013microglia interactions in neuroinflammation: Mechanisms, disease dynamics, and therapeutic strategies","volume":"44","author":"Zhang","year":"2025","journal-title":"Antioxid. Redox Signal."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cant, R., Dalgleish, A.G., and Allen, R.L. (2017). Naltrexone inhibits IL-6 and TNF\u03b1 production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00809"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/bph.13394","article-title":"Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4","volume":"173","author":"Wang","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/acs.jcim.7b00717","article-title":"Dissecting the innate immune recognition of opioid inactive isomer (+)-naltrexone\u2013derived toll-like receptor 4 antagonists","volume":"58","author":"Zhang","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1021\/acs.jmedchem.3c02316","article-title":"Exploring the function of (+)-naltrexone precursors: Their activity as TLR4 antagonists and potential in treating morphine addiction","volume":"67","author":"Gao","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/imj.15430","article-title":"Central sensitivity and fibromyalgia","volume":"51","author":"Mezhov","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11481-013-9451-y","article-title":"Treatment of complex regional pain syndrome (CRPS) using low-dose naltrexone (LDN)","volume":"8","author":"Chopra","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.31128\/AJGP-09-22-6564","article-title":"Low-dose naltrexone in the treatment of fibromyalgia: A systematic review and narrative synthesis","volume":"52","author":"Aitcheson","year":"2023","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11916-025-01411-1","article-title":"Low dose naltrexone in the management of chronic pain syndrome: A meta-analysis of randomized controlled clinical trials","volume":"29","author":"Hegde","year":"2025","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/1753-0407.13202","article-title":"Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial","volume":"13","author":"Srinivasan","year":"2021","journal-title":"J. Diabetes"},{"key":"ref_39","first-page":"682","article-title":"Use of low-dose naltrexone in the management of posttraumatic trigeminal neuropathic pain: A retrospective case series","volume":"56","author":"Ananthan","year":"2025","journal-title":"Quintessence Int."},{"key":"ref_40","first-page":"E393","article-title":"Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review","volume":"24","author":"Soin","year":"2021","journal-title":"Pain Physician"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clinthera.2023.03.013","article-title":"Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: A randomized, double-blind, placebo-controlled, crossover clinical trial","volume":"45","author":"Lew","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.adaj.2020.08.019","article-title":"Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review","volume":"151","author":"Hatfield","year":"2020","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Raknes, G., and Sm\u00e5brekke, L. (2019). Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis: A nationwide register-based controlled quasi-experimental before-after study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223545"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110966","DOI":"10.1016\/j.intimp.2023.110966","article-title":"Low-dose naltrexone use for the management of post-acute sequelae of COVID-19","volume":"124","author":"Bonilla","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.clinthera.2023.12.009","article-title":"Low-dose naltrexone improves post-COVID-19 condition symptoms","volume":"46","author":"Tamariz","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1573397113666170321120329","article-title":"Low dose naltrexone in the treatment of fibromyalgia","volume":"14","author":"Metyas","year":"2018","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e15638","DOI":"10.1016\/j.heliyon.2023.e15638","article-title":"A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia","volume":"9","author":"Partridge","year":"2023","journal-title":"Heliyon"},{"key":"ref_48","first-page":"320","article-title":"Is low-dose naltrexone effective in chronic pain management?","volume":"72","author":"Radi","year":"2023","journal-title":"J. Fam. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamaneurol.2019.2917","article-title":"Scientific advances in and clinical approaches to small-fiber polyneuropathy: A review","volume":"76","author":"Oaklander","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.2147\/JPR.S561662","article-title":"Real-world effectiveness and tolerability of low dose naltrexone to treat chronic pain: A retrospective cohort study of one pain physician\u2019s practice","volume":"18","author":"Aalto","year":"2025","journal-title":"J. Pain Res."},{"key":"ref_51","first-page":"e86538","article-title":"Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia","volume":"17","author":"Zapata","year":"2025","journal-title":"Cureus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jtos.2020.12.003","article-title":"Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain","volume":"20","author":"Dieckmann","year":"2021","journal-title":"Ocul. Surf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s11064-023-03938-4","article-title":"Acute low dose naltrexone increases \u03b2-endorphin and promotes neuronal recovery following hypoxia-ischemic stroke in type 2 diabetic mice","volume":"48","author":"Kumari","year":"2023","journal-title":"Neurochem. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jpain.2013.12.007","article-title":"Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain","volume":"15","author":"Ellis","year":"2014","journal-title":"J. Pain"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13041-022-00960-5","article-title":"Toll-like receptors and their role in neuropathic pain and migraine","volume":"15","author":"Liu","year":"2022","journal-title":"Mol. Brain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1474-4422(24)00076-0","article-title":"Complex regional pain syndrome: Advances in epidemiology, pathophysiology, diagnosis, and treatment","volume":"23","author":"Ferraro","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/JPR.S389957","article-title":"Low-dose naltrexone (LDN) for chronic pain at a single institution: A case series","volume":"16","author":"Boorman","year":"2023","journal-title":"J. Pain Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"17448069211006617","DOI":"10.1177\/17448069211006617","article-title":"Review of complex regional pain syndrome and the role of the neuroimmune axis","volume":"17","author":"Prasad","year":"2021","journal-title":"Mol. Pain"},{"key":"ref_59","first-page":"187","article-title":"Nonopioid pharmacologic management of chronic noncancer pain","volume":"112","author":"Sokol","year":"2025","journal-title":"Am. Fam. Physician"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2147\/JPR.S451183","article-title":"Effective doses of low-dose naltrexone for chronic pain: An observational study","volume":"17","author":"Marcus","year":"2024","journal-title":"J. Pain Res."},{"key":"ref_61","first-page":"30","article-title":"Low dose naltrexone in conjunction with the Wahls Protocol to reduce the frequency of chronic migraines in a patient with multiple sclerosis: A case study","volume":"20","author":"Codino","year":"2021","journal-title":"Integr. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"135248","DOI":"10.1016\/j.neulet.2020.135248","article-title":"Low-dose naltrexone reverses facial mechanical allodynia in a rat model of trigeminal neuralgia","volume":"736","author":"Medeiros","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1150","DOI":"10.1097\/PR9.0000000000001150","article-title":"Abstracts from the International Pelvic Pain Society (IPPS) annual scientific meeting on pelvic pain 2023","volume":"9","author":"Lamvu","year":"2024","journal-title":"Pain Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00677","DOI":"10.1016\/j.crwh.2024.e00677","article-title":"Low-dose naltrexone as a treatment for vulvodynia: A case series","volume":"45","author":"Sullender","year":"2025","journal-title":"Case Rep. Womens Health"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1535370218817746","article-title":"Intermittent blockade of OGFr and treatment of autoimmune disorders","volume":"243","author":"Zagon","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-018-1427-5","article-title":"Low-dose naltrexone for induction of remission in inflammatory bowel disease patients","volume":"16","author":"Lie","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/j.jpainsymman.2025.08.015","article-title":"Low dose naltrexone for refractory cancer pain: Case series of initial safety and effectiveness","volume":"70","author":"Malik","year":"2025","journal-title":"J. Pain Symptom Manag."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14737140.2022.2037426","article-title":"Naltrexone at low doses (LDN) and its relevance to cancer therapy","volume":"22","author":"Liu","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s12325-020-01591-9","article-title":"Naltrexone\u2019s impact on cancer progression and mortality: A systematic review of studies in humans, animal models, and cell cultures","volume":"38","author":"Liubchenko","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/ADM.0000000000001421","article-title":"Drug-induced liver injury due to medications for alcohol use disorder: Results from the DILIN prospective study","volume":"19","author":"Gopalakrishna","year":"2025","journal-title":"J. Addict. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bolton, M., Hodkinson, A., Boda, S., Moud, A., Panagioti, M., Rhodes, S., Riste, L., and Van Marwijk, H. (2019). Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: A systematic review and meta-analysis. BMC Med., 17.","DOI":"10.1186\/s12916-018-1242-0"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamapsychiatry.2025.3035","article-title":"Over-the-counter naltrexone to address unhealthy alcohol use","volume":"83","author":"Terechin","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","article-title":"Naltrexone depot formulations for opioid and alcohol dependence: A systematic review","volume":"17","author":"Lobmaier","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"ENEURO.0087-21.2021","DOI":"10.1523\/ENEURO.0087-21.2021","article-title":"Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and \u03b2-endorphin","volume":"8","author":"Metz","year":"2021","journal-title":"eNeuro"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/3\/151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:46:40Z","timestamp":1772790400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/3\/151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jpm16030151"],"URL":"https:\/\/doi.org\/10.3390\/jpm16030151","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}